Skip to main content
EPRX
NASDAQ Life Sciences

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$7.89
Mkt Cap
$485.26M
52W Low
$3.667
52W High
$9.32
52W Position info
115% above low
Off High info
15% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

EPRX has more than doubled off its 52-week low of $3.667.

Summary

Eupraxia Pharmaceuticals announced the appointment of Dr. Jeymi Tambiah as its new Chief Medical Officer, replacing the retiring Dr. Mark Kowalski, who will transition to a senior consultant role.


Key Events · Executive and Board Changes · EPRX

  • New Chief Medical Officer Appointed

    Dr. Jeymi Tambiah has been appointed as the new Chief Medical Officer, bringing over 18 years of experience in clinical development, medical, and regulatory strategy.

  • Outgoing CMO Retires

    Dr. Mark Kowalski, the current CMO, is retiring but will serve as a senior consultant to ensure a smooth transition.

  • Strengthens Clinical Leadership

    Dr. Tambiah's background as a Board Certified Cardiothoracic Surgeon and his track record in advancing immunology programs are expected to drive late-stage development and pipeline expansion, particularly for EP-104GI in Eosinophilic Esophagitis.


Analysis · EPRX · Life Sciences

The appointment of Dr. Jeymi Tambiah as Chief Medical Officer is a significant executive leadership change for Eupraxia Pharmaceuticals, a clinical-stage biotechnology company. Dr. Tambiah brings extensive experience in clinical development, medical, and regulatory strategy, which is crucial as the company advances its EP-104GI program in Eosinophilic Esophagitis and expands its gastroenterology pipeline. The smooth transition with the retiring CMO, Dr. Mark Kowalski, serving as a consultant, mitigates potential disruption and ensures continuity in clinical strategy.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EPRX was trading at $7.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $485.3M. The 52-week trading range was $3.67 to $9.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EPRX - Latest Insights

EPRX
Oct 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.30
Real-time Price: $6.29 info
Change: -$0.0100 (-0.16%) info
Market Cap: $422.445M info
EPRX
Sep 30, 2026, 8:04 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $8.45
Real-time Price: $6.29 info
Change: -$2.16 (-26%) info
Market Cap: $422.445M info
EPRX
Aug 13, 2026, 8:10 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $6.36
Real-time Price: $6.29 info
Change: -$0.070 (-1%) info
Market Cap: $422.445M info
EPRX
Aug 11, 2026, 5:24 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $6.70
Real-time Price: $6.29 info
Change: -$0.410 (-6%) info
Market Cap: $422.445M info
EPRX
Jul 13, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $6.43
Real-time Price: $6.29 info
Change: -$0.140 (-2%) info
Market Cap: $422.445M info